Overview

NCI Definition: A rare mixed phenotype acute leukemia in which the blasts express B-lymphoid and myeloid lineage markers but are negative for MLL translocation and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable. [1]

Mixed phenotype acute leukemia, B/myeloid, NOSs most frequently harbor alterations in TP53, TET2, RUNX1, DNMT3A, and FLT3 [2].

Most Commonly Altered Genes in Mixed Phenotype Acute Leukemia, B/Myeloid, NOS

TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Exon 8 Mutation, and TET2fs are the most common alterations in mixed phenotype acute leukemia, B/myeloid, NOS [2].

Top Alterations in Mixed Phenotype Acute Leukemia, B/Myeloid, NOS

Significant Genes in Mixed Phenotype Acute Leukemia, B/Myeloid, NOS

ABL1 +

ABL2 +

BCR +

CEP72 +

CRLF2 +

EPOR +

FGFR1 +

FGFR2 +

FGFR3 +

FGFR4 +

FLT3 +

IL7R +

JAK1 +

JAK2 +

JAK3 +

LYN +

NTRK1 +

NTRK2 +

NTRK3 +

PDGFRA +

PDGFRB +

SH2B3 +

TYK2 +

Disease Details

Synonyms
Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified
Parent(s)
Mixed Phenotype Acute Leukemia
OncoTree Name
Mixed Phenotype Acute Leukemia, B/Myeloid, NOS
OncoTree Code
MPALBNOS

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.